Spero Therapeutics (SPRO) Net Margin (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Net Margin came in at 232.91% in Q4 2025, up 27458676.0% YoY from N/an in Q4 2024, and up 100.2% on a QoQ basis from 115558.33% in Q1 2025.
Spero Therapeutics (SPRO) Net Margin (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 10 years of Net Margin data on file, last reported at 232.91% in Q4 2025.
- Quarterly Net Margin rose 27458676.0% year-over-year to 232.91% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 901.37% (up 94775.0% YoY) and the FY2025 annual result came in at 40.99%, up 5149194.0% from the prior year.
- Net Margin climbed to 232.91% in Q4 2025, from 115558.33% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 1044.41% in Q4 2021 to a low of 274353.85% in Q4 2024.
- A 5-year average of 25388.04% and a median of 898.05% in 2021 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2024 — Net Margin sank 27455697 bps — and 2025, when it surged 27458676 bps.
- Tracing SPRO's Net Margin over 5 years: stood at 1044.41% in 2021, then tumbled by 153 bps to 550.63% in 2022, then surged by 137 bps to 203.12% in 2023, then plunged by 135170 bps to 274353.85% in 2024, then soared by 100 bps to 232.91% in 2025.
- The last three Net Margin figures came in at 232.91% (Q4 2025), 115558.33% (Q1 2025), and 274353.85% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,862.02% |
| Dec 31, 2025 | 232.91% |
| Mar 31, 2025 | -115,558.33% |
| Dec 31, 2024 | -274,353.85% |
| Sep 30, 2024 | -25,455.38% |
| Jun 30, 2024 | -175.19% |
| Mar 31, 2024 | -9,045.00% |
| Dec 31, 2023 | 203.12% |
| Sep 30, 2023 | -12.55% |
| Jun 30, 2023 | -438.48% |
| Mar 31, 2023 | -5,948.43% |
| Dec 31, 2022 | -550.63% |
| Sep 30, 2022 | -1,093.90% |
| Jun 30, 2022 | -2,910.04% |
| Mar 31, 2022 | -13,800.00% |
| Dec 31, 2021 | 1,044.41% |
| Sep 30, 2021 | -7,871.47% |
| Jun 30, 2021 | -702.20% |
| Mar 31, 2021 | -549.67% |
| Sep 30, 2020 | -77,239.47% |